Isogenica Enters into Research and License Agreement with Wyeth
CAMBRIDGE, England,1st June 2007: Isogenica Ltd, today announced that it has entered into a research and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE).
Under the terms of the agreement, Isogenica will use its CIS display technology to select therapeutic peptide candidates to an unspecified number of Wyeth targets. The company will receive research fees and milestone and royalty payments for the development and commercialization of any products resulting from the collaboration.
Isogenica's CIS display technology provides a novel and effective means of rapidly identifying peptides that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.
"We look forward to building a strong and long lasting relationship
with Wyeth and in assisting them with their therapeutic discovery
activities" said Dr. Kevin FitzGerald, Isogenica's CEO. "We believe
that peptides, and especially those discovered and matured for
enhanced in vivo performance using CIS display technology,
represent a very rich source of compounds for therapeutic and other
in vivo applications."
Notes to editors
About Isogenica
Isogenica was formed in December 2000 to develop and commercialize
innovative in vitro molecular evolution technologies. The company
has its research facility at the Babraham Research Campus,
Cambridge UK.
Isogenica's core technology, CIS display, can be applied to the
discovery of new antibody, peptide and polypeptide drug candidates,
to the discovery of high specificity diagnostic compounds and to
the isolation of target validation and other research reagents,
purification reagents and environmental detection reagents.
Contact details:
Isogenica Ltd
Kevin FitzGerald, PhD MBA, CEO
+44 (0) 1223 496720
kevin.fitzgerald@isogenica.com
Northbank Communications
Gemma Price / Holly Griffiths / Katja Stout
+44 (0)20 7268 3002
g.price@northbankcommunications.com
Holly Griffiths Account Executive ------------------------------------------------------------------------ ----------------------- Direct line: +44 (0)20 7268 3241 Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102 www.northbankcommunications.com <http://www.northbankcommunications.com>
Northbank Communications Ltd 85 Tottenham Court Road, London, W1T 4TQ, UK
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
